Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-30
2011-08-30
Dunston, Jennifer (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S007600, C514S009500, C424S085100, C435S375000
Reexamination Certificate
active
08008254
ABSTRACT:
Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of cytokines are disclosed and claimed.
REFERENCES:
patent: 5197985 (1993-03-01), Caplan et al.
patent: 5199942 (1993-04-01), Gillis
patent: 5202120 (1993-04-01), Silver et al.
patent: 5543318 (1996-08-01), Smith et al.
patent: 5580779 (1996-12-01), Smith et al.
patent: 5602301 (1997-02-01), Field
patent: 5833975 (1998-11-01), Paoletti et al.
patent: 5906934 (1999-05-01), Grande et al.
patent: 5942235 (1999-08-01), Paoletti
patent: 5990091 (1999-11-01), Tartaglia et al.
patent: 6001934 (1999-12-01), Yamanaka et al.
patent: 6004777 (1999-12-01), Tartaglia et al.
patent: 6099832 (2000-08-01), Mickle et al.
patent: 6110459 (2000-08-01), Mickle et al.
patent: 6117675 (2000-09-01), Van der Kooy et al.
patent: 6130066 (2000-10-01), Tartaglia et al.
patent: 6174333 (2001-01-01), Kadiyala et al.
patent: 6255292 (2001-07-01), Liang
patent: 6265189 (2001-07-01), Paoletti et al.
patent: 6329348 (2001-12-01), Crystal et al.
patent: 6547787 (2003-04-01), Altman et al.
patent: 2002/0122792 (2002-09-01), Stegmann
patent: 1136083 (2001-09-01), None
patent: 11-246433 (1999-09-01), None
patent: WO 92/11865 (1992-07-01), None
patent: WO 95/12979 (1995-05-01), None
patent: WO 95/14079 (1995-05-01), None
patent: WO 95/28174 (1995-10-01), None
patent: WO 95/34581 (1995-12-01), None
patent: WO 96/04314 (1996-02-01), None
patent: WO 96/38544 (1996-12-01), None
patent: WO 99/45775 (1999-09-01), None
patent: WO 00/06195 (2000-02-01), None
patent: WO 00/06710 (2000-02-01), None
patent: WO 00/57922 (2000-10-01), None
patent: WO 01/26694 (2001-04-01), None
patent: WO 01/34179 (2001-05-01), None
patent: WO 01/85193 (2001-11-01), None
patent: WO 01/94420 (2001-12-01), None
Burkitt et al., “Wheater's Functional History: A Text and Colour Atlas.” 3rdEdition, New York: Churchill Livingstone, 1996, pp. 107-111.
Huang, Jul-Han et al. “Protein Transfer of Preformed MHC-Peptide Complexes Sensitizes Target Cells to T Cell Cytolysis,”Immunity, vol. 1: 607-613, Oct. 1994.
Ross, Russell, “The pathogenesis of atherosclerosis: a perspective for the 1990s,” Nature, vol. 362: 801-809, Apr. 1993.
Sensebe, Luc, et al., The Broad Spectrum of Cytokine Gene Expression by Myoid Cells from the Human Marrow Microenvironment,Stem Cells, vol. 15: 133-143, Nov. 2, 1997.
Wartiovaara, Ulla, et al., “Peripheral Blood Platelets Express VEGF-C and VEGF which are Released during Platelet Activation,”Thromb Haemost, vol. 80: 171-175, 1998.
Mohle, Robert, et al., “Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets,”Proc. Natl. Acad. Sci. USA, vol. 94: 663-668, Jan. 21, 1997.
Boyden, Stephen, “The Chemotactic Effect of Mixtures of Antibody and Antigen on Polymorphonuclear Leucocytes,”J. Exptl. Med.vol. 115: 453-456, 1962.
American Heart Association. 2001 Heart and Stroke Statistical Update. Dallas, Texas: American Heart Association, 2000.
Bautz, F. et al., “Expression and secretion of vascular endothelial growth factor-A by cytokine stimulated hematopoietic progenitor cells. Possible role in the hernatopoietic microenvironment.”Exp Hematol, vol. 28(6):700-706, Jun. 2000, Abstract.
Beardsle, M. A. et al., “Rapid turnover of connexin43 in the adult rat heart.”Circ. Res.vol. 83: 629-635, 1998.
Beltrami, C.A. et al., “Structural basis of end-stage failure in ischemic cardiomyopathy in humans.”Circulationvol. 89: 151-163, 1994.
Bianco, P. et al. “Bone marrow stromal stem cells: nature, biology, and potential applications.”Stem Cellsvol. 19:180-192, 2001.
Blume et al., “A review of autologous hematopoietic cell transplantation.”Biology of Blood&Marrow Transplantation, vol. 6: 1-12, 2000.
Bodine, D.M. et al., “Efficient retrovirus transduction of mouse pluripotent hematopoietic stem cells mobilized into the peripheral blood by treatment with granulocyte colony-stimulating factor and stem cell factor.”Blood ,vol. 84: 1482-1491, 1994.
Breier, G. et al., “Molecular cloning and expression of murine vascular endothelial-cadherin in early stage development of cardiovascular system.”Blood, vol. 87: 630-641, 1996.
Brugger et al., “Ex vivo manipulation of hematopoietic stem and progenitor cells.”Seminars in Hematology, vol. 37 (1): 42-49, 2000.
Caceres-Cortes, J.R. et al., “Steel factor sustains SCL expression and the survival of purified CD34+ bone marrow cells in the absence of detectable cell differentiation.”Stem Cellsvol. 19(1):59-70, Jan. 2001, Abstract only.
Chiu et al., “Cellular Cardiomyoplasty: Mycardial Regeneration With Satellite Cell Implantation.”Ann. Thorac. Surg., vol. 60: 12-18, 1995.
Clutterbuck, R.D. et al., “G-CSF mobilization of haemopoietic cell populations in SCID mice engrafted with human leukaernia.”Bone Marrow Transplant, vol. 20(4):325-332, Aug. 1997, Abstract only.
Couper, L.L. et al., “Vascular endothelial growth factor increases the mitogenic response to fibroblast growth factor-2 in vascular smooth muscle cells in vivo via expression of fms-like tyrosine kinase-1.”Circ. Res., vol. 81: 932-939, 1997.
Durocher, D. et al., “The cardiac transcription factors Nkx2-5 and GATA-4 are mutual cofactors.”EMBO J., vol. 16: 5687-5696, 1997.
Fielding et al., “Autologous bone marrow transplantation.”Curr. Opin. Hematology, vol. 1: 412-417, 1994.
Gussoni et al., “Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation.”Nature, vol. 356:435-438, 1992.
Hermann, H. and Aebi, U. “In Subcellular Biochemistry: Intermediate Filaments.” vol. 31 (ed. Henmann, H. & Harris, E.): 319-362 (Plenum Press, New York, 1998).
Huang H.M. et al., “Optimal proliferation of a hematopoietic progenitor cell line requires either costitnulation with stem cell factor or increase of receptor expression that can be replaced by over expression of Bcl-2.”Blood, vol. 93(8):2569-2577, Apr. 1999.
Ikuta, K. et al., “Mouse hematopoietic stem cells and the interaction of c-kit receptor and steel factor.”International Journal of Cell Cloning, vol. 9:451-460, 1991, Abstract only.
Janowska-Wieczorek, A. et al., “Autocrine/paracrine mechanisms in human hematopoiesis.”Stem Cells, vol. 19:99-107, 2001.
Jo, D.Y. et al., “Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1 .”The Journal of Clinical Investigation, vol. 105(1): 101-111, Jan. 2000.
Kachinsky, A.M. et al., “Intermediate filaments in cardiac myogenesis: nestin in the developing mouse heart.”J. Histochem. Cytochem., vol. 43: 843-847, 1995.
Kanj et al., “Myocardial ischemia associated with high-dose carmustine infusion.”,Cancer, vol. 68 (9):1910-1912, 1991.
Kajstura, J. et al., “The cellular basis of pacing-induced dilated cardiomyopathy. Myocyte cell loss and myocyte cellular reactive hypertrophy.”Circulation, vol. 92: 2306-2317, 1995.
Kasahara, H. et al., “Cardiac and extracardiac expression of Csx/Nkx2.5 homeodomain protein.”Circ. Res., vol. 82: 936-946, 1998.
Keil F. et al., “Effect of interleukin-3, stem cell factor and granulocyte-macrophage colony-stimulating factor on committed stem cells: long-term culture initiating cells and bone marrow stroma in a one-step long-term bone marrow culture.”Ann. Hematol., vol. 79(5):243-248, May 2000.
Kempermann, G. et al., “Activity-dependent regulation of neuronal plasticity and self repair.”Prog Brain Res., vol. 127:35-48, 2000, Abstract only.
Kim, C.H. and Broxmeyer H.E., “In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment.
Cooley LLP
Dunston Jennifer
New York Medical College
LandOfFree
Methods and compositions for the repair and/or regeneration... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the repair and/or regeneration..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the repair and/or regeneration... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2725176